Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.66 EUR | +3.91% | +3.10% | +25.47% |
10:57am | Immutep, Merck Collaborate on Trial for Lung Cancer Therapy | MT |
07:20am | Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial | MT |
Evolution of the average Target Price on Immutep ADR
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Immutep ADR
Capital One Securities | |
Canaccord Genuity | |
Baird | |
Maxim | |
Ladenburg Thalmann |
EPS Revisions
- Stock Market
- Equities
- IMM Stock
- YP1A Stock
- Consensus Immutep ADR